Completed preclinical and clinical trials (see below) indicate that this novel agent has attributes that improve on native doxorubicin including reduction of adverse events, improvement in efficacy and the ability to reach the tumor more quickly.
Completed laboratory and clinical trials (see below) reveal that this new compound possesses characteristics superior to native doxorubicin, including decreased side effects, enhanced effectiveness, and faster access to the tumor.